Turkish
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

Black Raspberry Confection in Preventing Oral Cancer in Healthy Volunteers

Sadece kayıtlı kullanıcılar makaleleri çevirebilir
Giriş yapmak kayıt olmak
Bağlantı panoya kaydedilir
DurumAktif, işe alım değil
Sponsorlar
Ohio State University Comprehensive Cancer Center

Anahtar kelimeler

Öz

This clinical trial studies black raspberry confection in preventing oral cancer in healthy volunteers. Black raspberry contains ingredients that may prevent or slow the growth of certain cancers.

Açıklama

PRIMARY OBJECTIVES:

I. To select an optimal black raspberry confection based on altered gene expression and chemical profiles in healthy individuals exposed to 3 black raspberry-based amorphous functional confections with modulated bioactive release rate at two doses (4 g and 8 g).

OUTLINE: Participants are randomized to 1 of 6 arms after 2 weeks.

ARM I: Participants receive black raspberry (BRB) confection 1 fast release orally (PO) 4-6 hours apart thrice daily (TID) for 2 weeks.

ARM II: Participants receive BRB confection 2 fast release PO 4-6 hours apart TID for 2 weeks.

ARM III: Participants receive BRB confection 1 intermediate release PO 4-6 hours apart TID for 2 weeks.

ARM IV: Participants receive BRB confection 2 intermediate release PO 4-6 hours apart TID for 2 weeks.

ARM V: Participants receive BRB confection 1 prolonged release PO 4-6 hours apart TID for 2 weeks.

ARM VI: Participants receive BRB confection 2 prolonged release PO 4-6 hours apart TID for 2 weeks.

Tarih

Son Doğrulandı: 02/28/2019
İlk Gönderilen: 10/09/2013
Tahmini Kayıt Gönderildi: 10/10/2013
İlk Gönderilen: 10/13/2013
Son Güncelleme Gönderildi: 03/17/2019
Son Güncelleme Gönderildi: 03/18/2019
Fiili Çalışma Başlangıç Tarihi: 06/30/2013
Tahmini Birincil Tamamlanma Tarihi: 03/31/2020
Tahmini Çalışma Tamamlanma Tarihi: 03/31/2020

Durum veya hastalık

Healthy Volunteers

Müdahale / tedavi

Other: Fast release BRB confection

Other: Intermed release BRB confection

Other: Prolong release BRB confection

Evre

Evre 1

Kol Grupları

KolMüdahale / tedavi
Experimental: Arm I (Fast release BRB confection 4g)
Participants receive one fast release BRB confection (4g) PO 4-6 hours apart thrice daily (TID) for 2 weeks.
Experimental: Arm II (Fast release BRB confection 8g)
Participants receive two fast release BRB confection (8g) PO 4-6 hours apart TID for 2 weeks.
Experimental: Arm III (Intermed release BRBconfection 4g)
Participants receive one intermediate release BRB confection (4g) PO 4-6 hours apart TID for 2 weeks.
Experimental: Arm IV (Intermed release BRBconfection 8g)
Participants receive two intermediate release BRB confection (8g) PO 4-6 hours apart TID for 2 weeks.
Experimental: Arm V (Prolong release BRB confection 4g)
Participants receive one prolonged release BRB confection (4g) PO 4-6 hours apart TID for 2 weeks.
Experimental: Arm VI (Prolong release BRB confection 8g)
Participants receive two prolonged release BRB confection (8g) PO 4-6 hours apart TID for 2 weeks.

Uygunluk kriterleri

Çalışmaya Uygun Yaşlar 18 Years İçin 18 Years
Çalışmaya Uygun CinsiyetlerAll
Sağlıklı Gönüllüleri Kabul EdiyorEvet
Kriterler

Inclusion Criteria:

- Be healthy, free-living adults

- Be a non-smoker (defined as adults who have never smoked or who have not had a cigarette in the past ten years)

- Agree to consume a standardized vitamin/mineral supplement and avoid other nutrition and alternative supplements for the duration of the study

- Agree to follow a berry-restricted diet and to document any accidental consumption of restricted foods each day of the study

- Agree to abstain from mouthwashes

Exclusion Criteria:

- Have an active metabolic or digestive illness including malabsorptive disorders, renal insufficiency, hepatic insufficiency, cachexia, or short bowel syndrome

- Have an active or a recent history of any condition that causes altered immunity such as chronic inflammatory disease, autoimmune disorders, cancer, anemia, and blood dyscrasias

- Have a known allergy or food intolerance to ingredients in study products (black raspberries),other berries, wheat, or soy

- Are strict vegans (no consumption of animal, fish or egg products)

- Are planning to conceive, or are currently pregnant or lactating

- Are heavy alcohol consumers (defined as an average consumption of greater than 2 drinks/day)

- Have a history of oral cancer or currently undergoing treatment of oral cancer

- In the last month have had any active oral lesions or maladies or currently have any oral disease or obvious open sores in the oral cavity or surrounding the oral opening

- Have strong gag reflex or problems swallowing that prohibit buccal brushing of the oral cavity

- Have been on an antibiotic regime lasting for one week in the last 6 months

Sonuç

Birincil Sonuç Ölçütleri

1. Acceptance of candidate formulations, assessed using a 9 point hedonic scale (1 =dislike very much, 9 = like very much) [Up to day 14]

Compliance and safety of the confections will be evaluated using dietary and sensory questionnaires. The analysis of variance (ANOVA) style model accounting for the random effect of the individual subject and the fixed effect of the dissolution (amorphous confection form) group will be used to examine the effect of attribute data, gender, and age using a 9-point hedonic scale. The significant differences between means of the different groups will be examined using the Ryan-Einot-Gabriel-Welsch (REGW) multiple comparisons test.

2. Bioavailability index, defined as the average rank of BRB effect in anthocyanins, ellagic acid, urolithins, and quercetin derivatives [Up to day 14]

To select an optimal delivery vehicle & dose, a combination that results in any of 10 subjects having an adverse event will be eliminated in the 1st stage. In the 2nd and 3rd stages ANOVA style models accounting for the random effect of individual subject and the fixed effect of dose & release rate will be used to examine phytonutrient metabolite & gene expression. Using the multiple comparisons with the best procedure, any combination will be eliminated that is significantly worse than the best combination for a global index of bioavailability (stage 2) and gene expression effects (stage 3).

3. Gene expression index, defined as the average rank of BRB effect on expression of genes responsive to BRBs and important to smoking and inflammatory response [Up to day 14]

To select an optimal delivery vehicle & dose, a combination that results in any of 10 subjects having an adverse event will be eliminated in the 1st stage. In the 2nd and 3rd stages ANOVA style models accounting for the random effect of individual subject and the fixed effect of dose & release rate will be used to examine phytonutrient metabolite & gene expression. Using the multiple comparisons with the best procedure, any combination will be eliminated that is significantly worse than the best combination for a global index of bioavailability (stage 2) and gene expression effects (stage 3).

Facebook sayfamıza katılın

Bilim tarafından desteklenen en eksiksiz şifalı otlar veritabanı

  • 55 dilde çalışır
  • Bilim destekli bitkisel kürler
  • Görüntüye göre bitki tanıma
  • Etkileşimli GPS haritası - bölgedeki bitkileri etiketleyin (yakında)
  • Aramanızla ilgili bilimsel yayınları okuyun
  • Şifalı bitkileri etkilerine göre arayın
  • İlgi alanlarınızı düzenleyin ve haber araştırmaları, klinik denemeler ve patentlerle güncel kalın

Bir belirti veya hastalık yazın ve yardımcı olabilecek bitkiler hakkında bilgi edinin, bir bitki yazın ve karşı kullanıldığı hastalıkları ve semptomları görün.
* Tüm bilgiler yayınlanmış bilimsel araştırmalara dayanmaktadır

Google Play badgeApp Store badge